Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide tablets for weight loss are taken once a day, first thing in the morning, on a completely empty stomach, with no more than a small sip of plain water — and the timing of that first swallow matters more than most people expect. Sold in the UK as Wegovy tablets, oral semaglutide was approved by the MHRA in June 2026 as the first licensed oral GLP-1 medicine for weight management in the UK. Like all GLP-1 medicines, it is a prescription-only medicine: a prescriber reviews your health history before treatment begins, and guides any dose changes throughout. Getting the daily routine right from the start makes a real difference to how well the tablet is absorbed — and, in turn, to results.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Set the tablet beside a glass of plain water the night before. The moment you wake up, before the kettle, before coffee, before anything else, take the tablet with a sip of plain water, up to about 120 ml. Then wait. The absorption mechanism that makes oral semaglutide work depends on an entirely empty stomach and a neutral environment; food or drink in those first 30 minutes can cut the amount of medicine your body actually absorbs to a fraction of what the dose is designed to deliver. That is not a minor inconvenience, it is central to how the tablet functions, and it is why the NHS semaglutide patient page is explicit on the point.
Swallow the tablet whole. Do not crush, chew or split it. If you take other regular medicines in the morning, those wait at least 30 minutes too, check the specifics with your prescriber, because some medicines are more time-sensitive than others. Once the half-hour is up, eat, drink your coffee and carry on. That is the whole ritual. Simple, but the sequence cannot be shuffled.
One practical note: if you know a busy week is coming (a holiday, a Monday after a late payday shop, a period where mornings are chaotic) it is worth building the habit before you need it, not after. The routine becomes automatic within a week or two for most people.
The escalation ladder for Wegovy tablets runs 1.5 mg, then 4 mg, then 9 mg, then the 25 mg maintenance dose. Your prescriber sets the pace; the minimum at each level is one month, and moving up before your system has adjusted tends to produce more gastrointestinal side effects, not faster results. The starting dose exists to let your body settle, not to produce meaningful weight loss from day one.
Nausea is the most commonly reported side effect, particularly in the early weeks and after each increase. It is usually mild to moderate and tends to ease as your body adjusts. Other GI effects (loose stools, constipation, reflux, an unsettled stomach) follow a similar pattern. If symptoms feel severe or persist beyond a couple of weeks at a given dose, contact your prescriber rather than adjusting the dose yourself.
If you miss a day, take the tablet the following morning as normal. Do not double up. Consistent daily dosing matters more than perfect timing on any single occasion. For the full detail on missed doses and interactions, the prescriber's guidance and the Patient Information Leaflet that comes with your medicine are the definitive references, not a webpage, including this one. Our frequently asked questions cover some common day-to-day practicalities if you have general queries.
The OASIS 4 phase-3 trial) 307 adults with obesity or overweight and at least one weight-related condition, 64 weeks, versus placebo, alongside lifestyle changes, is the clinical foundation for this medicine. Average weight loss across all participants taking the tablet was around 13.6%, compared with about 2.4% in the placebo group. Among those who took the medicine consistently throughout the trial, the average reached close to 17%. That second figure gets quoted often, so it is worth being clear: it applies to full adherence, not to the average experience.
Both numbers are meaningful. So is the comparison with the injection form. If you are weighing up which route suits you, the comparison between the tablet and the injection covers that question in detail, including the trial evidence for each. The tablet is not simply a more convenient version of the same thing, the dosing schedule, the absorption mechanism and the practical demands are genuinely different, and that is worth understanding before you choose.
Wegovy tablets are not available on the NHS at present; a NICE appraisal would need to happen first. For now, they are available via private prescription only. A summary of cost considerations for the tablet is on our Wegovy tablet cost page if that is relevant to your decision. The medicine itself is a prescription-only medicine regardless of route, so suitability is always a clinical call.
Unlike the semaglutide injection, Wegovy tablets do not need refrigeration. Room-temperature storage is fine, which removes a practical complication that some people find off-putting about injectables. Keep them in the original packaging, away from excessive heat or direct sunlight, and check the Patient Information Leaflet for any specific storage conditions confirmed for the product you receive.
Travel is straightforward by comparison with the injection. No cool bag, no airport ice-pack anxiety, no questions about hotel fridges. That practical difference matters to a lot of people, it is one reason some prefer the tablet even when the injection might otherwise suit them clinically. Our page on semaglutide tablets covers more of the practical picture if you are still in the research stage.
A note on the name: Rybelsus is also oral semaglutide, but it is licensed for type 2 diabetes management, at different strengths (3 mg, 7 mg, 14 mg). Those strengths are not steps in the Wegovy tablet schedule, the weight-loss tablet runs 1.5 mg, 4 mg, 9 mg and 25 mg only. The two products have different licences, different dosing ladders and different indications. It matters because content online sometimes blurs the two; your prescriber will always be prescribing to the correct licensed indication.
If you are thinking about whether this treatment is right for you, our clinical team (including our lead prescriber, whose background is outlined on the clinical team profile) reviews every consultation personally. You can read more about how to use semaglutide tablets for weight loss, including guidance on how to take semaglutide tablets day to day and a broader look at how to take oral semaglutide correctly, before deciding. You can read more about the weight-loss treatments we support before deciding. When you are ready to take the next step, start your free consultation and a GPhC-registered prescriber will review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.